With JPM 2022 having finished up last week, new standout partnerships between promising biotech companies and profitable big pharma show that reciprocity between players…

Demographically, South Korea has been an appealing investment opportunity for pharma companies. It has a relatively large population of around 51 million people…

Discussion in biotech often focuses on new therapeutics and technologies being developed that have the potential to cure cancer and rare genetic diseases…